Pirtobrutinib

50 interactions 4 explained in plain English
Also sold as: Jaypirca Jaypirca®
About Pirtobrutinib

Pirtobrutinib is used to treat mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) in adults that has returned or is unresponsive to other treatments. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals c… Read the full Pirtobrutinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Colchicine Doxorubicin Entrectinib Nifedipine Midazolam Nasal Spray Fentanyl Transdermal Patch
1 Contraindicated 45 Major 4 Moderate
All (50) Contraindicated (1) Major (45) Moderate (4)

Contraindicated

Pirtobrutinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Pirtobrutinib Omeprazole Gastrobim Explained Increased sensitive CYP2C19 substrate exposure and an increased risk of sensitive CYP2C19 substrate-related adverse effects Details Pirtobrutinib Relugolix Orgovyx Explained Increased relugolix exposure Details Pirtobrutinib Simvastatin Flolipid Explained Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Acalabrutinib Calquence Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Pirtobrutinib Avapritinib Ayvakit Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Avanafil Stendra Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Bosutinib Bosulif Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Budesonide Entocort Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Budesonide Nasal Spray Rhinocort Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Budesonide Oral Inhalation Pulmicort Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Cobimetinib Cotellic Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Cyclosporine Injection Atopica Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Pirtobrutinib Cyclosporine Ophthalmic Cequa Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Pirtobrutinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Pirtobrutinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Pirtobrutinib Dasatinib Phyrago Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse effects Details Pirtobrutinib Dihydroergotamine Injection DHE-45® Injection Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Dihydroergotamine Nasal Spray Migranal Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Dofetilide Tikosyn Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Pirtobrutinib Entrectinib Rozlytrek Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Everolimus Afinitor Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Pirtobrutinib Felodipine Plendil® Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Fentanyl Transdermal Patch Duragesic® Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Finerenone Kerendia Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Ibrexafungerp Brexafemme Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Ibrutinib Imbruvica Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Ivabradine Corlanor Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Ketoconazole Topical Extina® Foam Increased pirtobrutinib exposure and an increased risk of pirtobrutinib-related adverse effects Details Pirtobrutinib Lansoprazole Prevacid Increased sensitive CYP2C19 substrate exposure and an increased risk of sensitive CYP2C19 substrate-related adverse effects Details Pirtobrutinib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Pirtobrutinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Pirtobrutinib Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Pirtobrutinib Lovastatin Altocor® Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Lurasidone Latuda Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Maraviroc Selzentry Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Pirtobrutinib Methylergonovine Methergine Increased methylergonovine exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.